Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US29082K1051
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG014L7D4G1
EMBC
Embecta Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Embecta Corp
ISIN
US29082K1051
TICKER
EMBC
MIC
XNAS
REUTERS
EMBC.OQ
BLOOMBERG
EMBC US
Mi., 24.06.2026       Embecta
US29082K1051

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) common stock between November 25, 2025 and May 4, 2026, inclusive (the “Clas...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, yo...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - June 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

NEW YORK, June 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"). A class...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) common stock between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”). Embecta investors have until August 17, 2026 to file a lead plaintiff motion.IF YOU...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) common stock between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”). Embecta investors have until August 17, 2026 to file a l...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - June 23, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

SAN FRANCISCO, June 23, 2026 /PRNewswire/ -- Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings report, apparently at odds with prior narrative...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Embecta
US29082K1051

NEW YORK, June 23, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appoin...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Embecta
US29082K1051

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025 and May 4, 2026. Embecta Corp., is a medical device company, that provides solutions to improve the health and wellb...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 22.06.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - June 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Embecta
US29082K1051

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMBECTA CO...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Embecta
US29082K1051

Law Offices of Howard G. Smith announces an investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMBECTA CORP. (EMBC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING C...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Embecta
US29082K1051

NEW YORK, June 22, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 19.06.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - June 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Embecta
US29082K1051

NEW YORK, June 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"). A class...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Embecta
US29082K1051

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026. Embecta describes itself as a “leading global medical device company focused on providing solutions to improve the health and well-being of people livi...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Embecta
US29082K1051

The Law Offices of Frank R. Cruz announces an investigation of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMBECTA CORP. (EMBC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOU...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Embecta
US29082K1051

The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of EMBC during the class per...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Embecta
US29082K1051

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors wh...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 17.06.2026       Embecta
US29082K1051

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025 and May 4, 2026. Embecta Corp., is a medical device company, that provides solutions to improve the health and wellbeing of people living with diabetes in the...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Embecta
US29082K1051

embecta announced that Nimish Muzumdar has been named the company’s Senior Vice President and President, North America, effective June 15, 2026....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Embecta
US29082K1051

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose i...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Embecta
US29082K1051

PARSIPPANY, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - May 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. ("Embecta Corp.") (NASDAQ: EMBC) concerning potential violations of the federal securities laws.On November 25, 2025, CFO Jacob P. Elguicze provided initial FY2026 revenue guidance of $1.071 billion...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Embecta
US29082K1051

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION]...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       Embecta
US29082K1051

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Embecta
US29082K1051

Embecta guided investors toward a $1.071-$1.093 billion revenue outlook for FY2026 while internal indicators reportedly already signaled the need for a cut -- shares later fell more than 25%. NEW YORK, May 13, 2026 /PRNewswire/ -- Shareholders who purchased Embecta Corp. (NASDAQ: EMBC) stock lost more than 25% of their investment value after the...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 08.05.2026       Embecta
US29082K1051

PARSIPPANY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Embecta
US29082K1051

New York, New York--(Newsfile Corp. - May 7, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. ("Embecta Corp.") (NASDAQ: EMBC) concerning potential violations of the federal securities laws.On November 25, 2025, CFO Jacob P. Elguicze provided initial FY2026 revenue guidance of $1.071 billion...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Embecta
US29082K1051

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 15, 2026 to stockholders of record at the close of business on May 28, 2026.About...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Embecta
US29082K1051

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter fiscal 2026 financial results....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Embecta
US29082K1051

PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal second quarter 2026 financial results, provide an operational update, and host...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Embecta
US29082K1051

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based medical supplies company Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic an...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Embecta
US29082K1051

Das Instrument JX7 US29082K1051 EMBECTA CORP. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 26.02.2026 und ex Dividende/Zinsen am 27.02.2026 The instrument JX7 US29082K1051 EMBECTA CORP. DL-,01 EQUITY has its pre-dividend/interest day on 26.02.2026 and its ex-dividend/interest day on 27.02.2026...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       Embecta
US29082K1051

embecta names new Chairman of the Board and Lead Independent Director...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Embecta
US29082K1051

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Embecta
US29082K1051

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 202...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Embecta
US29082K1051

PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Mo., 17.11.2025       Embecta
US29082K1051

David J. Albritton has resigned from the embecta Board for personal reasons and David F. Melcher, Non-Executive Chairman of the Board, plans to retire....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 14.11.2025       Embecta
US29082K1051

embecta and Direct Relief announce a significant expansion of their partnership to increase access to diabetes care for communities worldwide...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 08.08.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025....
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Fr., 08.08.2025       Embecta
US29082K1051

PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Do., 24.07.2025       Embecta
US29082K1051

PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink
Di., 27.05.2025       Embecta
US29082K1051

PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:...
Zur Nachricht
Embecta
Charts & Research Termsheets Terminal
Permalink